Advertisement

Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy

  • Nicholas B. Figura
  • Victoria T. Rizk
  • Homan Mohammadi
  • Brittany Evernden
  • Sepideh Mokhtari
  • H. Michael Yu
  • Timothy J. Robinson
  • Arnold B. Etame
  • Nam D. Tran
  • James Liu
  • Iman Washington
  • Roberto Diaz
  • Brian J. Czerniecki
  • Hatem Soliman
  • Hyo S. Han
  • Solmaz Sahebjam
  • Peter A. ForsythEmail author
  • Kamran A. AhmedEmail author
Brief Report
  • 69 Downloads

Abstract

Purpose

Leptomeningeal disease is a rare presentation of advanced metastatic breast cancer. The purpose of this study was to evaluate craniospinal progression between intrathecal (IT) trastuzumab, IT chemotherapy, and whole brain radiation therapy (WBRT) in leptomeningeal disease.

Methods

A total of 56 patients were identified with breast cancer leptomeningeal disease at our institution treated with IT trastuzumab (n = 18; 32%), single-agent IT chemotherapy (methotrexate n = 14 or thiotepa n = 1; 27%), or WBRT alone (n = 23; 41%). Patients were treated beginning November 2012 and followed until November 2018.

Results

Median time from breast cancer diagnosis to development of leptomeningeal disease was 4.3 years. There were no significant differences noted between IT trastuzumab, IT chemotherapy, or WBRT groups in age (p = 0.4), Karnofsky Performance Status (KPS) (p = 0.07), or receipt of systemic therapy at time of leptomeningeal disease treatment (p = 0.47). Median follow-up of patients from leptomeningeal diagnosis was 5 months (range 0.2–81.1 months). Significant differences were noted in Kaplan–Meier (KM) craniospinal progression-free survival (CS-PFS) with 6-month rates of 44%, 18%, and 26% (p = 0.04) between IT trastuzumab, IT chemotherapy, and WBRT, respectively. Craniospinal control > 10 months was achieved in four patients treated with IT trastuzumab. Twelve-month KM OS rates were 54%, 10%, and 19% (p = 0.01) between IT trastuzumab, IT chemotherapy, and WBRT groups, respectively. IT therapy was adequately tolerated with three patients undergoing treatment-related hospitalizations.

Conclusions

In our institutional series, significant differences were noted in CS-PFS and OS by treatment modality. IT trastuzumab should be considered in the management HER2+ breast leptomeningeal disease.

Keywords

Intrathecal trastuzumab Intrathecal herceptin HER2+ breast cancer Leptomeningeal disease 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872.  https://doi.org/10.1200/JCO.2004.12.149 CrossRefPubMedGoogle Scholar
  2. 2.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977.  https://doi.org/10.1002/cncr.11436 doiCrossRefPubMedGoogle Scholar
  3. 3.
    Bonneau C, Paintaud G, Tredan O, Dubot C, Desvignes C, Dieras V, Taillibert S, Tresca P, Turbiez I, Li J, Passot C, Mefti F, Mouret-Fourme E, Le Rhun E, Gutierrez M (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75–84.  https://doi.org/10.1016/j.ejca.2018.02.032 CrossRefPubMedGoogle Scholar
  4. 4.
    Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A (2016) Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol 34:e151–e155.  https://doi.org/10.1200/JCO.2012.44.8894 CrossRefPubMedGoogle Scholar
  5. 5.
    Brosnan EM, Anders CK (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163.  https://doi.org/10.21037/atm.2018.04.35 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Figura NB, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA (2018) Intrathecal trastuzumab in the management of HER2 + breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat 169:391–396.  https://doi.org/10.1007/s10549-018-4684-3 CrossRefPubMedGoogle Scholar
  7. 7.
    Kumthekar P, Gradishar W, Lin N, Pentsova E, Groves M, Jeyapalan S, Melisko M, Grimm S, Lassman AB, Raizer J (2018) Intrathecal (IT) trastuzumab (T) for the treatment of leptomeningeal metastases (LM) in patients (Pts) with human epidermal growth factor receptor 2-positive (HER2+) cancer: a multicenter phase 1/2 study. Neuro-oncology 20:Vi58CrossRefGoogle Scholar
  8. 8.
    Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, Andre C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neuro-oncol 113:83–92.  https://doi.org/10.1007/s11060-013-1092-8 CrossRefGoogle Scholar
  9. 9.
    Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617.  https://doi.org/10.1200/JCO.2004.01.175 CrossRefPubMedGoogle Scholar
  10. 10.
    Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL (2015) Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2 + breast cancer patient. J Immunother Cancer 3:41.  https://doi.org/10.1186/s40425-015-0084-y CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978–1980.  https://doi.org/10.1093/annonc/mdn654 CrossRefPubMedGoogle Scholar
  12. 12.
    Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM, Lad SP, Fecci PE (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8:73312–73328.  https://doi.org/10.18632/oncotarget.20272 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC (2016) Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis. Cancer Res Treat 48:843–847.  https://doi.org/10.4143/crt.2014.234 CrossRefPubMedGoogle Scholar
  14. 14.
    Pestalozzi BC, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18:2349–2351.  https://doi.org/10.1200/JCO.2000.18.11.2349 CrossRefPubMedGoogle Scholar
  15. 15.
    Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer—a systematic review. Oncotarget 7:3740–3747.  https://doi.org/10.18632/oncotarget.5911 PubMedGoogle Scholar
  16. 16.
    Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377PubMedGoogle Scholar
  17. 17.
    Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349–2354CrossRefPubMedGoogle Scholar
  18. 18.
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726.  https://doi.org/10.1200/JCO.2002.20.3.719 CrossRefPubMedGoogle Scholar
  19. 19.
    Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8.  https://doi.org/10.1186/s13058-015-0665-1 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M (2013) Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139:13–22.  https://doi.org/10.1007/s10549-013-2525-y CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Nicholas B. Figura
    • 1
  • Victoria T. Rizk
    • 2
  • Homan Mohammadi
    • 1
  • Brittany Evernden
    • 3
  • Sepideh Mokhtari
    • 3
  • H. Michael Yu
    • 1
  • Timothy J. Robinson
    • 1
  • Arnold B. Etame
    • 3
  • Nam D. Tran
    • 3
  • James Liu
    • 3
  • Iman Washington
    • 1
  • Roberto Diaz
    • 1
  • Brian J. Czerniecki
    • 4
  • Hatem Soliman
    • 4
  • Hyo S. Han
    • 4
  • Solmaz Sahebjam
    • 3
  • Peter A. Forsyth
    • 3
    Email author
  • Kamran A. Ahmed
    • 1
    Email author
  1. 1.Departments of Radiation OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Morsani College of MedicineUniversity of South FloridaTampaUSA
  3. 3.Departments of Neuro OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  4. 4.Departments of Breast OncologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations